Mark E. Boye

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2−negative metastatic breast cancer: experience from the patient perspective

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

Multimodal therapies for postoperative nausea and vomiting, and pain

EMT Transition States during Tumor Progression and Metastasis

Central sensitization: Implications for the diagnosis and treatment of pain

Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer

Development and validation of a composite score based on clinically meaningful events for the opioid-related symptom distress scale

Consensus Guidelines for the Management of Postoperative Nausea and Vomiting

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

Sensitization in patients with painful knee osteoarthritis

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer

Cardiovascular Effects of the Cyclooxygenase Inhibitors

Cyclo-oxygenase 2 inhibitors and the risk of anastomotic leakage after fast-track colonic surgery

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

Guidelines for Perioperative Care in Elective Colonic Surgery: Enhanced Recovery After Surgery (ERAS^®) Society Recommendations

Guidelines for Perioperative Care in Elective Rectal/Pelvic Surgery: Enhanced Recovery After Surgery (ERAS^®) Society Recommendations

Safety and Efficacy of the Cyclooxygenase-2 Inhibitors Parecoxib and Valdecoxib after Noncardiac Surgery

Validity of 24-h recall ratings of pain severity: Biasing effects of “Peak” and “End” pain

The economic burden of metastatic breast cancer: A systematic review of literature from developed countries

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial